See this31 Aug 2017 18:09
The cost of treatment, limited numbers, lifespan and competition has been noted by the market. Novartis sp hasn't reacted to the news either. Would hope in the coming weeks and months that 8-9p will be the bottom . This news was built into the recent rise. Interesting times to come. How much of the € 100 million will Oxb eventually see?